{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:47:08Z","timestamp":1791463628159,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Bionomics Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.lungcan.2013.05.006","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T17:15:55Z","timestamp":1371489355000},"page":"422-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"81","clinical-trial-number":[{"clinical-trial-number":"actrn12610000093088","registry":"10.18810\/anzctr"}],"author":[{"given":"Anna K.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenette","family":"Creaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Kremmidiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Bibby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabell F.","family":"Leske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.R.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2013.05.006_bib0005","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D","article-title":"Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma V","volume":"18","author":"Kumar-Singh","year":"1997","journal-title":"J Pathol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s004280050388","article-title":"Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma","volume":"435","author":"K\u00f6nig","year":"1999","journal-title":"Virchows Arch"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","article-title":"The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents","volume":"37","author":"Siemann","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0030","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1535-7163.MCT-09-0815","article-title":"BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy","volume":"9","author":"Kremmidiotis","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0035","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1158\/1078-0432.CCR-11-0937","article-title":"Clinical, pharmacodynamic and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation","volume":"17","author":"Rischin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0045","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1055-9965.EPI-10-0346","article-title":"Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma","volume":"19","author":"Creaney","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0060","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0065","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0070","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma: the NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0075","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0080","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","article-title":"Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow","volume":"21","author":"Stevenson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0085","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","article-title":"Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0090","first-page":"3408","article-title":"A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer","volume":"62","author":"Dowlati","year":"2002","journal-title":"Cancer Res"},{"issue":"15s","key":"10.1016\/j.lungcan.2013.05.006_bib0095","article-title":"Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: final phase II trial results","volume":"27","author":"Zwiefel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0100","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1200\/JCO.2011.35.0660","article-title":"Randomized phase III Placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer","volume":"29","author":"Lara","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0105","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0110","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"issue":"Suppl. 8","key":"10.1016\/j.lungcan.2013.05.006_bib0115","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80018-1","article-title":"Phase II trial of ZD0473 as second-line therapy in mesothelioma","volume":"38","author":"Giaccone","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2013.05.006_bib0120","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213002183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213002183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:30:43Z","timestamp":1770280243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500213002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0169500213002183"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.006","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}